A post hoc analysis of 2,384 tirzepatide-treated trial participants split them at week 8 by whether they had lost 5% of their body weight [1]. Those who had not still reached a clinically meaningful result by week 72. Theirs was significantly smaller than the early responders’.
If your weight has changed little after two months, the guide to why weight loss varies covers factors you can discuss with your prescriber. The analysis below follows people who started tirzepatide in two specific trials.
What was analyzed
Researchers took the tirzepatide-treated participants from the two SURMOUNT trials and sorted them by their week-8 result. That is 1,775 from the trial in people without type 2 diabetes and 609 from the trial in people with it, 2,384 in total. [1] Those who had lost at least 5% of their body weight by then were classed as early responders; those who had not were not. Both groups were then followed to week 72.
Early responders differed from the rest at baseline: they were more likely to be female, more likely to be White, and had lower starting HbA1c. That matters for how to read everything that follows, because nobody was assigned to a group. People sorted themselves by how their own bodies behaved.
What happened by week 72
Both groups achieved clinically meaningful weight reduction and improvements in cardiometabolic risk parameters including HbA1c. The early responders did significantly better on both.
At week 72, estimated mean weight loss was 23.3% for early responders and 14.6% for the other group in SURMOUNT-1. In SURMOUNT-2, which enrolled adults with type 2 diabetes, the estimates were 20.0% and 10.8%, respectively[1]. These are group averages.
What a year looks like outside a trial
A separate cohort of 14,046 US adults with a BMI of 30 or more measured mean twelve-month weight change in routine care[2]. It came to -13.0% on tirzepatide, -5.9% on semaglutide, and roughly -4.0% each on exenatide, dulaglutide and liraglutide. The observational design leaves room for differences between treatment groups.
The review of semaglutide outcomes in routine care explains why a clinic cohort and a trial can report different averages. If you are weighing the expense, the monthly price guide explains what published quotes cover. The study did not measure the cost of treatment.
How wide the spread is
A separate analysis grouped 135,349 patients by weight change[3]. The share who lost more than 15% ranged from 10% among Ozempic users to 34% among Zepbound users in this cohort.
Those four brands contain two active ingredients. Prescribing indications, doses and patient characteristics can differ by brand. The analysis of brand differences explains why these observational rates cannot isolate the effect of the product. Individual outcomes varied within each group.
The tolerability finding is the useful one
Gastrointestinal side effects had similar patterns, severity and timing in the two groups[1]. The researchers compared groups defined by early weight change.
The guide to GLP-1 side effects explains what patients may experience. In this analysis, similar patterns across groups did not establish whether one person’s nausea predicted their weight change.
What this cannot tell you
Whether becoming an early responder would help. Nobody was made into one. The comparison is between two groups of people who differed before the drug started and continued to differ after, so it describes prognosis rather than cause.
There is also no placebo arm inside this analysis. Only tirzepatide-treated participants were included. So “clinically meaningful” here is measured against where people started, not against an untreated comparison. Hold that distinction whenever a result is reported as change from baseline.
The money version of the question
If you are budgeting for treatment, the six-month cost tool can show how recurring charges add up. The trial averages cannot tell you how much weight you would lose over the same period.
Studies of how long people stay on treatment describe what happens in routine care. A separate study of persistence when treatment was free shows why price is only one part of that question. Ask your prescriber how to interpret your own progress.